Table 2. Patients in whom CMV-specific... | American Society of Hematology

Table 2.

Patients in whom CMV-specific cytotoxic T lymphocytes (CTL) were studied prospectively after allografting

Group/patient no.	Donor	HLA allele	CMV-specific CTL			CMV reactivation (days after SCT)	GVHD grade	Follow-up (days after SCT)
Group/patient no.	Donor	HLA allele	Day first detected	As % of CD8⁺ count at peak	Peak absolute cell count (× 10⁵ cells)	CMV reactivation (days after SCT)	GVHD grade	Follow-up (days after SCT)
Group 1 (recipient +/donor + for CMV)
1	S	A2	32	12	250	82	III	214
2	S	A2	31	1.5	53	ND	0	143
3	S	A2	31	0.7	2.1	ND	I	120
4	S	A2	48	3.3	369	ND	II	531
5	S	B7	43	10.1	409	ND	II	351
6	S	A2	21	21.0	162	ND	III	90 (90^†)
7	S	B7	55^*	3.2	195	47 & 139	III	338
8	S	A2	77^*	0.18	ND	ND	0	122
9	S	A2	81^*	4.6	310	52	II	516
10	V	B7	116	1.2-5	64	56 & 126	II	521
11	V	A2	112	5.9	20	20 & 150	III	337
12	V	A2; B7	100	0.1; 2.9	8.6; 112	27	0	210 (286^†)
Group 2 (recipient +/donor − for CMV)
13	S	A2	ND	ND	ND	ND	0	363
14	S	A2	ND	ND	ND	ND	0	193
15	V	A2	ND	ND	ND	ND	II	353
16	V	A2	ND	ND	ND	ND	0	161
17	V	A2	149	0.6	ND	33 & 114	III	208
Group 3 (recipient −/donor + for CMV)
18	S	B7	ND	ND	ND	ND	0	120
19	1 antigen m/m	A2	ND	ND	ND	ND	0	296
20	V	B7	160	0.8	4	ND	II	173 (201^†)
21	V	A2; B7	ND	ND	ND	ND	0	177 (232^†)
22	V	A2; B7	ND	ND	ND	ND	0	451
23	V	A2	ND	ND	ND	ND	0	392
24	V	A2	ND	ND	ND	ND	0	180

Group/patient no.	Donor	HLA allele	CMV-specific CTL			CMV reactivation (days after SCT)	GVHD grade	Follow-up (days after SCT)
Group/patient no.	Donor	HLA allele	Day first detected	As % of CD8⁺ count at peak	Peak absolute cell count (× 10⁵ cells)	CMV reactivation (days after SCT)	GVHD grade	Follow-up (days after SCT)
Group 1 (recipient +/donor + for CMV)
1	S	A2	32	12	250	82	III	214
2	S	A2	31	1.5	53	ND	0	143
3	S	A2	31	0.7	2.1	ND	I	120
4	S	A2	48	3.3	369	ND	II	531
5	S	B7	43	10.1	409	ND	II	351
6	S	A2	21	21.0	162	ND	III	90 (90^†)
7	S	B7	55^*	3.2	195	47 & 139	III	338
8	S	A2	77^*	0.18	ND	ND	0	122
9	S	A2	81^*	4.6	310	52	II	516
10	V	B7	116	1.2-5	64	56 & 126	II	521
11	V	A2	112	5.9	20	20 & 150	III	337
12	V	A2; B7	100	0.1; 2.9	8.6; 112	27	0	210 (286^†)
Group 2 (recipient +/donor − for CMV)
13	S	A2	ND	ND	ND	ND	0	363
14	S	A2	ND	ND	ND	ND	0	193
15	V	A2	ND	ND	ND	ND	II	353
16	V	A2	ND	ND	ND	ND	0	161
17	V	A2	149	0.6	ND	33 & 114	III	208
Group 3 (recipient −/donor + for CMV)
18	S	B7	ND	ND	ND	ND	0	120
19	1 antigen m/m	A2	ND	ND	ND	ND	0	296
20	V	B7	160	0.8	4	ND	II	173 (201^†)
21	V	A2; B7	ND	ND	ND	ND	0	177 (232^†)
22	V	A2; B7	ND	ND	ND	ND	0	451
23	V	A2	ND	ND	ND	ND	0	392
24	V	A2	ND	ND	ND	ND	0	180

For patients who were positive for both HLA A*0201 and HLA B*0702, the results for the HLA A*0201 tetramer are shown first, followed by the results for the B*0702 tetramer.

S indicates sibling; V, volunteer unrelated donor; ND, not detected; and 1 HLA antigen mismatch.

First sample studied.

†

Day of death.

View Large

This Feature Is Available To Subscribers Only